Low dose CE-MRA

Kambiz Nael, John M. Moriarty, J. Paul Finn

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Over the last decade, three-dimensional contrast-enhanced magnetic resonance angiography (CE-MRA) has emerged as a widely accepted and powerful technique for diagnostic assessment of almost all vascular territories. Its non-invasive nature and lack of ionizing radiation, its potential to cover a large field of view and the safety of gadolinium-based contrast agents make CE-MRA an appealing alternative to digital subtraction angiography (DSA) or computed tomography angiography (CTA). However, recent reports linking high dose gadolinium-based contrast agents to the development of nephrogenic systemic fibrosis [1-3] have raised concerns over the safety of CE-MRA. As a result, many investigators have focused attention on gadolinium dose reduction strategies [4,5]. This article reviews existing state-of-the-art 3D CE-MRA strategies to reduce contrast dose and summarizes current applications and clinical experience to date. It also highlights evolving techniques, which the authors feel are likely to enhance the future impact of CE-MRA.

Original languageEnglish (US)
Pages (from-to)2-8
Number of pages7
JournalEuropean Journal of Radiology
Volume80
Issue number1
DOIs
StatePublished - Oct 2011
Externally publishedYes

Fingerprint

Magnetic Resonance Angiography
Gadolinium
Contrast Media
Nephrogenic Fibrosing Dermopathy
Safety
Digital Subtraction Angiography
Ionizing Radiation
Blood Vessels
Research Personnel

Keywords

  • Contrast-enhanced magnetic resonance angiography (CE-MRA)
  • Digital subtraction angiography (DSA)
  • Gadolinium dose
  • Nephrogenic systemic fibrosis (NSF)
  • Time resolved MR angiography (TR-MRA)

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Low dose CE-MRA. / Nael, Kambiz; Moriarty, John M.; Finn, J. Paul.

In: European Journal of Radiology, Vol. 80, No. 1, 10.2011, p. 2-8.

Research output: Contribution to journalArticle

Nael, K, Moriarty, JM & Finn, JP 2011, 'Low dose CE-MRA', European Journal of Radiology, vol. 80, no. 1, pp. 2-8. https://doi.org/10.1016/j.ejrad.2011.01.092
Nael, Kambiz ; Moriarty, John M. ; Finn, J. Paul. / Low dose CE-MRA. In: European Journal of Radiology. 2011 ; Vol. 80, No. 1. pp. 2-8.
@article{7f4e46b077a94ca3aa9c84459c9e0e8c,
title = "Low dose CE-MRA",
abstract = "Over the last decade, three-dimensional contrast-enhanced magnetic resonance angiography (CE-MRA) has emerged as a widely accepted and powerful technique for diagnostic assessment of almost all vascular territories. Its non-invasive nature and lack of ionizing radiation, its potential to cover a large field of view and the safety of gadolinium-based contrast agents make CE-MRA an appealing alternative to digital subtraction angiography (DSA) or computed tomography angiography (CTA). However, recent reports linking high dose gadolinium-based contrast agents to the development of nephrogenic systemic fibrosis [1-3] have raised concerns over the safety of CE-MRA. As a result, many investigators have focused attention on gadolinium dose reduction strategies [4,5]. This article reviews existing state-of-the-art 3D CE-MRA strategies to reduce contrast dose and summarizes current applications and clinical experience to date. It also highlights evolving techniques, which the authors feel are likely to enhance the future impact of CE-MRA.",
keywords = "Contrast-enhanced magnetic resonance angiography (CE-MRA), Digital subtraction angiography (DSA), Gadolinium dose, Nephrogenic systemic fibrosis (NSF), Time resolved MR angiography (TR-MRA)",
author = "Kambiz Nael and Moriarty, {John M.} and Finn, {J. Paul}",
year = "2011",
month = "10",
doi = "10.1016/j.ejrad.2011.01.092",
language = "English (US)",
volume = "80",
pages = "2--8",
journal = "Journal of Medical Imaging",
issn = "0720-048X",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Low dose CE-MRA

AU - Nael, Kambiz

AU - Moriarty, John M.

AU - Finn, J. Paul

PY - 2011/10

Y1 - 2011/10

N2 - Over the last decade, three-dimensional contrast-enhanced magnetic resonance angiography (CE-MRA) has emerged as a widely accepted and powerful technique for diagnostic assessment of almost all vascular territories. Its non-invasive nature and lack of ionizing radiation, its potential to cover a large field of view and the safety of gadolinium-based contrast agents make CE-MRA an appealing alternative to digital subtraction angiography (DSA) or computed tomography angiography (CTA). However, recent reports linking high dose gadolinium-based contrast agents to the development of nephrogenic systemic fibrosis [1-3] have raised concerns over the safety of CE-MRA. As a result, many investigators have focused attention on gadolinium dose reduction strategies [4,5]. This article reviews existing state-of-the-art 3D CE-MRA strategies to reduce contrast dose and summarizes current applications and clinical experience to date. It also highlights evolving techniques, which the authors feel are likely to enhance the future impact of CE-MRA.

AB - Over the last decade, three-dimensional contrast-enhanced magnetic resonance angiography (CE-MRA) has emerged as a widely accepted and powerful technique for diagnostic assessment of almost all vascular territories. Its non-invasive nature and lack of ionizing radiation, its potential to cover a large field of view and the safety of gadolinium-based contrast agents make CE-MRA an appealing alternative to digital subtraction angiography (DSA) or computed tomography angiography (CTA). However, recent reports linking high dose gadolinium-based contrast agents to the development of nephrogenic systemic fibrosis [1-3] have raised concerns over the safety of CE-MRA. As a result, many investigators have focused attention on gadolinium dose reduction strategies [4,5]. This article reviews existing state-of-the-art 3D CE-MRA strategies to reduce contrast dose and summarizes current applications and clinical experience to date. It also highlights evolving techniques, which the authors feel are likely to enhance the future impact of CE-MRA.

KW - Contrast-enhanced magnetic resonance angiography (CE-MRA)

KW - Digital subtraction angiography (DSA)

KW - Gadolinium dose

KW - Nephrogenic systemic fibrosis (NSF)

KW - Time resolved MR angiography (TR-MRA)

UR - http://www.scopus.com/inward/record.url?scp=80052784373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052784373&partnerID=8YFLogxK

U2 - 10.1016/j.ejrad.2011.01.092

DO - 10.1016/j.ejrad.2011.01.092

M3 - Article

C2 - 21458187

AN - SCOPUS:80052784373

VL - 80

SP - 2

EP - 8

JO - Journal of Medical Imaging

JF - Journal of Medical Imaging

SN - 0720-048X

IS - 1

ER -